clinical trial tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 Responsiveness to Tirzepatide vs clinical

Following the use of GLP-1 agonists, patients may also present with symptoms warranting further targeted imaging evaluation

The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease

This triagonist pattern shapes metabolic signalling across several pathways

This comparison draws on peer-reviewed clinical data, FDA documentation, and the latest Phase 3 trial results to give you the most complete, evidence-based picture available

In individuals with insulin resistance (type 2 diabetes), preserved or elevated C-peptide levels indicate adequate insulin production with poor cellular response

Using advanced diagnostic tools and minimally invasive treatments, we help patients across Texas achieve long-term relief and better digestive wellness